Sildenafil citrate for the treatment of pulmonary arterial hypertension

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 6, 2006, Pages 825-828

  Antoniu, Sabina A ^a  

^a Clinic of Pulmonary Disease   (Romania)

Author keywords

Efficacy; Pulmonary arterial hypertension; Safety; Sildenafil citrate

Indexed keywords

ANTICOAGULANT AGENT; BERAPROST; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; CARDIAC GLYCOSIDE; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; UNIPROST;

ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FUNCTION; HUMAN; LUNG ARTERY PRESSURE; ORTHOSTATIC HYPOTENSION; PULMONARY HYPERTENSION; QUALITY OF LIFE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; UNSPECIFIED SIDE EFFECT;

HUMANS; HYPERTENSION, PULMONARY; PIPERAZINES;

EID: 33645821030     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.6.825     Document Type: Article

References (13)

1. GALIE N, GHOFRANI HA, TORBICKI A et al.: Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl J. Med. (2005) 353(20):2148-2157.
2. WILKINS MR, PAUL GA, STRANGE JW et al.: Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am. J. Respir. Crit. Care Med. (2005) 171(11):1292-1297.
3. SIMONNEAU G, GALIE N, RUBIN LJ et al.: Clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. (2004) 43(12 Suppl. S):5S-12S.
4. HUMBERT M, SITBON O, SIMONNEAU G: Treatment of pulmonary arterial hypertension. N. Engl. J. Med. (2004) 351(14):1425-1436.
5. GHOFRANI HA, PEPKE-ZABA J, BARBERA JA et al.: Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2004) 43(12 Suppl. S):68S-72S.
6. BADESCH DB, ABMAN SH, AHEARN GS et al.: Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest (2004) 126(1 Suppl.):35S-62S.
7. BARST RJ, MCGOON M, TORBICKI A et al.: Diagnosis and differential assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2004) 43(12 Suppl. S):40S-47S.
8. WHARTON J, STRANGE JW, MOLLER GM et al.: Antiprofiferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am. J. Respir. Crit. Care Med. (2005) 172(1):105-113.
9. SCHERMULY RT, KREISSELMEIER KP, GHOFRANI HA et al: Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. (2004) 169(1):39-45.
10. DUNKERN TR, HATZELMANN A: The effect of sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5. Cell Signal. (2005) 17(3):331-339.
11. BARST RJ, RUBIN LJ, LONG WA et al.: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. (1996) 334(5):296-302.
12. OLSCHEWSKI H, SIMONNEAU G, GALIE N et al.: Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. (2002) 347(5):322-329.
13. RUBIN LJ, BADESCH DB, BARST RJ et al.: Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. (2002) 346(12):896-903.